Zimmer Biomet Holdings Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone. I'm Robbie Marcus, the Medtech analyst at JPMorgan. I'm very happy to have Zimmer Biomet here for our next session. I'm going to introduce first, Bryan Hanson, CEO; and Suky. And Suky, I apologize, but I just go with Suky, as I'm sure a lot of people do, my apologies. I want to let everyone know in the JPMorgan Healthcare Conference website, you can go ahead and click Ask A Question or feel free to e-mail me or just hit me on Bloomberg chat, and I will do my best to work your questions into the session here.
First, Bryan, I thought we'd start off with everybody's favorite topic, which is COVID-19 and fourth quarter and current trends into 2021. We didn't get a pre-announcement from you, but we've heard certainly, Smith & Nephew preannounced this morning. We've had some other large-cap competitors make comments on trends. And the latest we got from you was earlier in December. So I thought maybe we could just start off on the COVID recovery. Any comments you can make on fourth quarter and how that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |